Hayat Pharmaceutical Industries Co. PLC (ASE:HPIC)

ASE:HPIC Income Statement

Financials in millions JOD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	16.71	15.81	17.11	16.58	16.58
Revenue Growth (YoY)	5.72%	-7.61%	3.15%	0.02%	5.99%
Cost of Revenue	7.41	5.93	6.01	5.39	5.2
Gross Profit	9.3	9.88	11.09	11.19	11.38
Selling, General & Admin	1.87	6.36	6.45	6.21	6.7
Research & Development	-	0.66	0.58	0.47	0.35
Other Operating Expenses	-	0.02	-0.14	-0.05	-0.05
Operating Expenses	1.87	7.04	6.89	6.77	7.2
Operating Income	7.43	2.84	4.2	4.42	4.19
Interest Expense	-0.15	-0.1	-0.07	-0.09	-0.11
Other Non Operating Income (Expenses)	-3.74	-	-	-	-
EBT Excluding Unusual Items	3.54	2.74	4.14	4.33	4.08
Pretax Income	3.54	2.74	4.14	4.33	4.08
Income Tax Expense	0.45	0.41	0.61	0.69	0.57
Net Income	3.09	2.33	3.53	3.64	3.51
Net Income to Common	3.09	2.33	3.53	3.64	3.51
Net Income Growth	32.73%	-34.04%	-3.12%	3.75%	5.36%
Shares Outstanding (Basic)	10	10	10	10	10
Shares Outstanding (Diluted)	10	10	10	10	10
EPS (Basic)	0.33	0.25	0.37	0.38	0.37
EPS (Diluted)	0.33	0.25	0.37	0.38	0.37
EPS Growth	32.73%	-34.04%	-3.12%	3.75%	5.36%
Free Cash Flow	-	2.44	2.23	3.95	3.05
Free Cash Flow Per Share	-	0.26	0.24	0.42	0.32
Dividend Per Share	-	0.165	0.250	0.250	0.200
Dividend Growth	-	-34.00%	0%	25.00%	100.00%
Gross Margin	55.64%	62.50%	64.85%	67.48%	68.65%
Operating Margin	44.45%	17.96%	24.58%	26.67%	25.25%
Profit Margin	18.49%	14.73%	20.63%	21.96%	21.17%
Free Cash Flow Margin	-	15.45%	13.07%	23.80%	18.39%
EBITDA	8.57	3.93	5.26	5.32	4.67
EBITDA Margin	51.27%	24.84%	30.74%	32.09%	28.14%
D&A For EBITDA	1.14	1.09	1.05	0.9	0.48
EBIT	7.43	2.84	4.2	4.42	4.19
EBIT Margin	44.45%	17.96%	24.58%	26.67%	25.25%
Effective Tax Rate	12.67%	15.07%	14.68%	15.91%	13.96%

Source: S&P Capital IQ. Standard template. Financial Sources.